Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Dispatches

In Ukraine, HIV takes hold with a vengeance

Aranka Anema
CMAJ September 03, 2002 167 (5) 534;
Aranka Anema
Amsterdam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Of the 40 million people currently living with HIV/AIDS, 36 million do not have access to the antiretroviral (ARV) therapy that would prolong their lives. According to the UN, 96% of people infected with HIV live in developing countries where they do not have access to treatment. Humanitarian activist organizations argue that the HIV/AIDS pandemic is fuelled, in part, by industrialized countries' failure to mobilize promised resources for prevention, treatment and advocacy. HIV/AIDS is currently causing an estimated 10 000 deaths a day.

Figure

Figure. Act Up, a Paris-based advocacy group, called for a stop to “medical apartheid” during the XIV International AIDS Conference, and criticized the G8's failure to mobilize its promised $10-billion a year plan for HIV/AIDS prevention and treatment. It also criticized Coca-Cola for failing to provide its African workers with HIV/AIDS treatment. Photo by: MSF

International discussion over the last 2 decades has emphasized prevention as the key to reducing HIV/AIDS prevalence. However, those attending the XIV International AIDS Conference in Barcelona in July saw a new focus on treatment. Presentations highlighted the interdependent relationship between treatment, prevention and advocacy: it is only by treating people, prolonging their lives and preserving their dignity that HIV/AIDS prevention can be effectively advocated and supported.

In 1999, Médecins Sans Frontières (MSF), a nonprofit international humanitarian organization, launched its Access to Essential Medicines Campaign. It aims to raise international awareness about the access-to-drug crisis and advocate for lower prices. The campaign also encourages renewed production of “abandoned” drugs and stimulates research and development for neglected diseases. MSF now treats 1000 patients with ARV therapy in some 20 programs in Africa, Asia, Europe and Latin America. One of its most successful treatment programs is in Ukraine, which has the highest rate of HIV/AIDS infection in Europe and the former Soviet Union and one of the fastest growing rates worldwide. According to UN estimates, 300 000 Ukrainians — 1% of the adult population — have become infected with HIV since 1995. Women and children are particularly vulnerable because they are often left without social or medical assistance.

MSF has been involved in HIV/ AIDS programs in Southern Ukraine since 1999. HIV/AIDS prevention and treatment programs for target groups such as HIV-positive mothers are currently under way in 3 cities, including Odessa. These programs focus on preventing mother-to-child transmission and providing voluntary counselling and testing, as well as treatment with ARVs such as nevirapine. Since their inception, more than 300 mother–child pairs have been treated in the program, resulting in a 4-fold reduction in mother-to-child transmission.

Although the results are promising, most Ukrainians living with HIV/AIDS have no access to treatment due to the exorbitant cost of ARVs. Under a spring 2002 agreement, the Ukrainian government and several international pharmaceutical companies reduced the cost of ARV therapy from US$1900 to US$1700 per patient per year. MSF is not impressed, arguing that by registering generic drugs and allowing them on the Ukrainian market, the cost of ARV treatment could be reduced to US $350. Joost van der Meer, head of the MSF mission, explains that “market competition between generic companies and the other manufacturers brings down prices for HIV/AIDS drugs much more than closed-door deals between governments and individual pharmaceutical companies.” In a country where the average monthly income is US $60 and only 15% of the population has access to health care, the reductions offered by pharmaceutical companies are insufficient.

At the Barcelona conference, MSF called for generic competition in developing countries in order to reduce ARV prices. It also asked for increased domestic and international funding to improve prevention and treatment efforts. MSF believes that an equity-access approach that encourages competition and local production should eventually reduce the international cost of ARV treatment to about US$50 per patient annually. — Aranka Anema, Medical Editor, Program Operations, MSF Headquarters, Amsterdam

PreviousNext
Back to top

In this issue

CMAJ
Vol. 167, Issue 5
3 Sep 2002
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In Ukraine, HIV takes hold with a vengeance
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
In Ukraine, HIV takes hold with a vengeance
Aranka Anema
CMAJ Sep 2002, 167 (5) 534;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
In Ukraine, HIV takes hold with a vengeance
Aranka Anema
CMAJ Sep 2002, 167 (5) 534;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • The G8 fails global health
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • South African brain drain costing $5 billion — and counting
  • In South Africa, only the funeral industry is booming
Show more Dispatches

Similar Articles

Collections

  • Topics
    • Global health
    • HIV & AIDS

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire